BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xing T, Xu H, Cao L, Ye M. HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis. PLoS One 2017;12:e0169444. [PMID: 28107377 DOI: 10.1371/journal.pone.0169444] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Wong WWL, Pechivanoglou P, Wong J, Bielecki JM, Haines A, Erman A, Saeed Y, Phoon A, Tadrous M, Younis M, Rayad NZ, Rac V, Janssen HLA, Krahn MD. Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials. Syst Rev 2019;8:207. [PMID: 31426837 DOI: 10.1186/s13643-019-1126-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
2 Fonseca MA, Ling JZJ, Al-Siyabi O, Co-Tanko V, Chan E, Lim SG. The efficacy of hepatitis B treatments in achieving HBsAg seroclearance: A systematic review and meta-analysis. J Viral Hepat 2020;27:650-62. [PMID: 32170983 DOI: 10.1111/jvh.13283] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
3 Abdulla M, Ghuloom M, Nass H, Mohammed N, Farid E, ALQamish J. Prevalence of hepatitis B e antigenemia in Bahraini hepatitis B patients: A retrospective, single-center study. JGH Open 2021;5:337-42. [PMID: 33732879 DOI: 10.1002/jgh3.12494] [Reference Citation Analysis]
4 Ciupe SM. Modeling the dynamics of hepatitis B infection, immunity, and drug therapy. Immunol Rev 2018;285:38-54. [PMID: 30129194 DOI: 10.1111/imr.12686] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
5 Wang ML, Chen EQ, Zhang DM, Du LY, Yan LB, Zhou TY, Lei XZ, Lei BJ, Lu JJ, Liao J, Tang H. Efficacy and safety of three adefovir-based combination therapies in HBeAg-positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy. J Viral Hepat 2017;24 Suppl 1:21-8. [PMID: 29082645 DOI: 10.1111/jvh.12792] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Mueller-Breckenridge AJ, Garcia-Alcalde F, Wildum S, Smits SL, de Man RA, van Campenhout MJH, Brouwer WP, Niu J, Young JAT, Najera I, Zhu L, Wu D, Racek T, Hundie GB, Lin Y, Boucher CA, van de Vijver D, Haagmans BL. Machine-learning based patient classification using Hepatitis B virus full-length genome quasispecies from Asian and European cohorts. Sci Rep. 2019;9:18892. [PMID: 31827222 DOI: 10.1038/s41598-019-55445-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
7 Geng J, Bao H, Chen Y, Shi L, Geng J, Wang Q, Yu H. Nucleos(t)ide analogues for the treatment of chronic hepatitis B: a systematic review with network meta-analysis. Expert Rev Anti Infect Ther 2020;18:823-34. [PMID: 32329638 DOI: 10.1080/14787210.2020.1760843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Guo R, Xie Y, Yang J, Lu H, Ye P, Jin L, Lin W. Increasing plasma ADAMTS13 activity is associated with HBeAg seroconversion in chronic hepatitis B patients during 5 years of entecavir treatment. Sci Rep 2019;9:5916. [PMID: 30976044 DOI: 10.1038/s41598-019-42421-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Lai MW, Hsu CW, Lin CL, Chien RN, Lin WR, Chang CS, Liang KH, Yeh CT. Multiple doses of hepatitis B recombinant vaccine for chronic hepatitis B patients with low surface antigen levels: a pilot study. Hepatol Int. 2018;12:456-464. [PMID: 30088198 DOI: 10.1007/s12072-018-9890-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
10 Wen S, Tsai C, Cheng L, Huang C, Kuo W. Predictors of HBeAg loss after nucleos(t)ide analogues treatment for chronic hepatitis B: A preliminary finding. Adv in Digestive Med 2021;8:10-8. [DOI: 10.1002/aid2.13190] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Yang J, Guo R, Yan D, Lu H, Zhang H, Ye P, Jin L, Diao H, Li L. Plasma Level of ADAMTS13 or IL-12 as an Indicator of HBeAg Seroconversion in Chronic Hepatitis B Patients Undergoing m-ETV Treatment. Front Cell Infect Microbiol 2020;10:335. [PMID: 32793509 DOI: 10.3389/fcimb.2020.00335] [Reference Citation Analysis]
12 Hsu CW, Chu YD, Lai MW, Lin CL, Liang KH, Lin YH, Yeh CT. Hepatitis B Virus Covalently Closed Circular DNA Predicts Postoperative Liver Cancer Metastasis Independent of Virological Suppression. Cancers (Basel) 2021;13:538. [PMID: 33572617 DOI: 10.3390/cancers13030538] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Zhang C, Chen Y, Liang X, Zhang G, Ma H, Nie L, Wang Y. Detection of Hepatitis B Virus M204I Mutation by Quantum Dot-Labeled DNA Probe. Sensors (Basel) 2017;17:E961. [PMID: 28445403 DOI: 10.3390/s17050961] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]